Status:
WITHDRAWN
Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
Lead Sponsor:
Case Comprehensive Cancer Center
Conditions:
Malignant Neoplasm of Prostate
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to look at whether F-18 Fluciclovine (i.e. Axumin) is better or as good as F-18 Sodium Fluoride (F-18 NaF) when looking at bone disease from prostate cancer. Axumin is a r...
Detailed Description
The study will assess the diagnostic performance of \[F-18\] fluciclovine PET/CT compared to \[F-18\] NaF PET/CT as the reference standard. Each bone lesion identified on \[F-18\] NaF PET/CT will be c...
Eligibility Criteria
Inclusion
- Referred for initial staging or restaging of prostate cancers with clinical suspicion of bone metastases.
- Must understand and voluntarily sign an Informed Consent Document
Exclusion
- Cannot tolerate imaging up to 60 minutes of total imaging
Key Trial Info
Start Date :
March 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04765423
Start Date
March 25 2021
End Date
March 18 2022
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106